Danon disease is a rare X-linked dominant disorder caused by a primary deficiency in lysosome-associated membrane protein 2 (LAMP2). It is characterized by the development of hypertrophic cardiomyopathy in male teenagers, mild myopathy, and mental retardation.1,2 Electrocardiogram (EKG) usually displays a Wolff-Parkinson-White (WPW) syndrome. Females who carry the mutation in the LAMP2 gene on chromosome X could develop dilated or hypertrophic cardiomyopathy in their early 40s. Unfortunately, there is no causal therapy for Danon disease. Heart transplantation is the only therapeutic option once heart failure occurs and should be considered as early as possible due to the disease's rapid progression.3
Since Danon disease is rare, it is often misdiagnosed with hypertrophic cardiomyopathy or other causes of left ventricular hypertrophy (LVH). It should be highly suspected in the male teenager with LVH, especially if the patient has an extensive scarring pattern in the lateral wall on late gadolinium enhancement cardiac magnetic resonance (CMR), elevated creatine kinase and liver transaminase enzymes, and/or WPW syndrome. Endomyocardial biopsy and genetic analysis can confirm the diagnosis.47 This report demonstrates the clinical value of CMR for the diagnostic work-up of Danon disease, with diagnostic confirmation by endomyocardial biopsy and genetic analysis.
A 21-year-old Pakistani male college student with a 7-year history of muscle cramps and easy fatigability and dyspnea on exertion for the past few months presented to the local emergency department complaining of shortness of breath. He was found to have an enlarged heart on chest X-ray along with an abnormal EKG and was referred to our hospital for further evaluation. His mother had died of unknown etiology at age 40. His physical examination was significant for tachypnea, tachycardia, mild limb muscle weakness, and atrophy. Electrocardiogram showed sinus tachycardia with biventricular hypertrophy and short PR interval (Figure 1 A). Laboratory testing revealed elevations of serum creatine kinase and liver transaminase enzymes. Transthoracic echocardiography (TTE) demonstrated massive concentric LVH (septum 27 mm, lateral wall 21 mm) and severe globally depressed left ventricle (LV) systolic function with ejection fraction (EF) of 25 (Figure 1 B). The patient was further evaluated with CMR, which revealed morphologic findings similar to those of the TTE: severe symmetric LVH, severe LV systolic dysfunction, and moderate globally depressed right ventricular (RV) systolic function with a RVEF of 38. There was diffuse late gadolinium enhancement in the RV insertion points and mid-myocardium, most prominent in the LV lateral segments, with total scar burden of 63. These unusual extensive scarring patterns were suggestive of Danon disease (Figure 2). A definite LV apical thrombus was also found (Figure 3). Cardiac biopsy was performed in the subendocardial muscle of the RV septum, and no fibrosis, amyloid, or inflammation was observed. There was mild focal architectural disarray. The cardiomyocytes were hypertrophic, with enlarged and irregular nuclei and vacuolated cytoplasm (Figure 4 A). Ultrastructural examination showed numerous vacuoles containing degenerating mitochondria, glycogen, small vesicles, and granular debris (Figure 4 B).
Due to the constellation of findings, the patient underwent a hypertrophic cardiomyopathy genetic panel and was found to be heterozygous for a novel frameshift mutation in the LAMP2 gene, thus confirming the diagnosis of Danon disease. An electrophysiologic study was performed and failed to demonstrate any evidence of accessory pathways. In light of the patient's family history, symptoms, and echocardiographic findings, he was discharged home with a LifeVest device (ZOLL Medical Corporation, Burlington, MA), anticoagulant therapy, and optimal heart failure medications. Unfortunately, 3 months after discharge from Houston Methodist Hospital, the patient returned to his home country and died suddenly while hiking with his father.
We present the case of Danon disease confirmed by endomyocardial biopsy. In our case, the late gadolinium enhancement was mainly visible in the mid-myocardium and more extensively in the lateral segments in a distribution that would be unusual in more common pathologies.2 Given the poor prognosis of this disease, early recognition is important to guide therapeutic interventions.